News Sort by Year All Years 2023 (18) 2022 (31) 2021 (33) 2020 (37) 2019 (7) 2018 (4) Search October 2, 2023 TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines September 28, 2023 TFF Pharmaceuticals to Participate in Upcoming Investor Conferences August 23, 2023 TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023 August 17, 2023 TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option August 15, 2023 TFF Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 15, 2023 TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock August 14, 2023 TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock August 9, 2023 TFF Pharmaceuticals to Hold Second Quarter 2023 Financial and Business Results Conference Call on August 15, 2023 July 31, 2023 TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program for Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Pulmonary Aspergillosis and Other Voriconazole Responsive Fungal Pulmonary Infections June 26, 2023 TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine